Understanding how to control blood stem cell environments to reduce health risks.
Official title: Controlling the Niche to Control Clonal Hematopoiesis
Funded at Weill Medical Coll of Cornell Univ · NIH-11133971 · Data updated 2026-11-12
This study is looking at how certain mutated blood stem cells, which can lead to serious health problems, grow and change their surroundings to survive better, especially when your body needs more blood cells, and the goal is to find ways to help healthy stem cells while making it harder for the mutated ones to thrive, which could lead to new treatments for people with clonal hematopoiesis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | June 10, 2025 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $802,301 |
| NIH project number | 1R01HL175556-01A1 |
| Project ID | NIH-11133971 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with clonal hematopoiesis or those at risk of developing related blood disorders.
✕Less likely to help
Patients without clonal hematopoiesis or those with unrelated blood disorders may not benefit from this research.
What this research studies
This research investigates the mechanisms behind clonal hematopoiesis (CH), a condition where mutated blood stem cells increase the risk of serious health issues like strokes and blood cancers. The team aims to understand how these mutated cells change their surrounding environment, or niche, to promote their own expansion, especially during times of increased blood cell demand. By identifying the signals that activate and deactivate this niche, the researchers hope to develop strategies to protect healthy stem cells while making it difficult for the mutated ones to thrive. This could lead to new treatments that target the root causes of CH.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that reduce the risks associated with clonal hematopoiesis, potentially improving patient outcomes and quality of life.
How similar studies have gone: While the specific approach of controlling the stem cell niche in clonal hematopoiesis is novel, related research has shown promise in understanding blood cell dynamics and their environments.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Scandura, Joseph Michael — Weill Medical Coll of Cornell Univ
- Study coordinator: Scandura, Joseph Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.